| Maryse Palardy, MD | |
|
1500 East Medical Center Drive, Level 3, Ann Arbor, MI 48109-5856 | |
| (888) 287-1082 | |
| Not Available |
| Full Name | Maryse Palardy |
|---|---|
| Gender | Female |
| Speciality | Advanced Heart Failure And Transplant Cardiology |
| Experience | 23 Years |
| Location | 1500 East Medical Center Drive, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073865341 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 4301101785 (Michigan) | Primary |
| 207R00000X | Internal Medicine | 4301101785 (Michigan) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Covenant Medical Center | Saginaw, MI | Hospital |
| Beaumont Hospital Royal Oak | Royal oak, MI | Hospital |
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Bronson Methodist Hospital | Kalamazoo, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study ("BREAK-3" trial) published Online First in the Lancet.
Several probiotic products are marketed as effective treatments for acute diarrhoea in children, but a study published on bmj.com today finds that not all of these preparations are effective.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.
Personalized medicine has the potential to improve the treatment and care of patients. This promising approach has already borne fruit, with a handful of targeted therapies for cancer now in use.
› Verified 1 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868353 PECOS PAC ID: 3779496856 Enrollment ID: O20031106000325 |
News Archive
A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study ("BREAK-3" trial) published Online First in the Lancet.
Several probiotic products are marketed as effective treatments for acute diarrhoea in children, but a study published on bmj.com today finds that not all of these preparations are effective.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.
Personalized medicine has the potential to improve the treatment and care of patients. This promising approach has already borne fruit, with a handful of targeted therapies for cancer now in use.
› Verified 1 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952331936 PECOS PAC ID: 3779496856 Enrollment ID: O20031117000265 |
News Archive
A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study ("BREAK-3" trial) published Online First in the Lancet.
Several probiotic products are marketed as effective treatments for acute diarrhoea in children, but a study published on bmj.com today finds that not all of these preparations are effective.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.
Personalized medicine has the potential to improve the treatment and care of patients. This promising approach has already borne fruit, with a handful of targeted therapies for cancer now in use.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maryse Palardy, MD 3621 South State Street, 700 Kms Place, Ann Arbor, MI 48108 Ph: (734) 936-2047 | Maryse Palardy, MD 1500 East Medical Center Drive, Level 3, Ann Arbor, MI 48109-5856 Ph: (888) 287-1082 |
News Archive
A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study ("BREAK-3" trial) published Online First in the Lancet.
Several probiotic products are marketed as effective treatments for acute diarrhoea in children, but a study published on bmj.com today finds that not all of these preparations are effective.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.
Personalized medicine has the potential to improve the treatment and care of patients. This promising approach has already borne fruit, with a handful of targeted therapies for cancer now in use.
› Verified 1 days ago
Nabil Alkhoury Fallouh, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, 3rd Floor Taubman Ctr Recp B, Ann Arbor, MI 48109 Phone: 734-936-5582 | |
Sameer Dev Saini, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. David Alexander Stewart, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, 12th Floor C.s. Mott Children's Hospital Room 525, Ann Arbor, MI 48109 Phone: 734-763-5302 Fax: 734-647-5624 | |
Dr. Aiman M Mahmood, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Med Inn C728, Ann Arbor, MI 48109 Phone: 734-998-0891 | |
Anastasia Irene Wasylyshyn, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Katherine Saber Salisbury, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4260 Plymouth Rd, Ann Arbor, MI 48109 Phone: 734-764-6831 | |
Anne Lewis Carlton, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-647-5900 |